Blue water biotech teams with upscripthealth to launch telemedicine platform for benign prostatic hyperplasia asset, entadfi®

Cincinnati, july 25, 2023 (globe newswire) -- blue water biotech, inc. (“blue water” or the “company”) (nasdaq: bwv), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today announced an agreement with upscripthealth (“upscript”) to generate a robust, online telemedicine platform to distribute blue water's benign prostatic hyperplasia (“bph”) asset, entadfi®.
BWV Ratings Summary
BWV Quant Ranking